Preimplantation genetic diagnosis (PGD) is the genetic profiling of
embryos before they are implanted and can also be of oocytes before
fertilization. It is an adjuvant technique to in vitro fertilization
(IVF), used for the detection of genetic conditions or diseases prior
to the embryo being implanted. PGD is utilized for the screening of a
wide range of medical abnormalities such as inheritable diseases,
Down’s syndrome, and traits of a number of other physiological
abnormalities. In addition, the utilization of array comparative
genomic hybridization (aCGH) as well as fluorescent in situ
hybridization (FISH) techniques within PGD has enhanced the overall
success rate and process efficiency of pregnancy via IVF.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=427
As per the report, the delay in conception among women has raised the
demand for PGD. In addition, the rising occurrence of genetic
diseases prompts patients to undergo PGD cycles in order to have a
disease-free offspring. Increasing lifestyle changes such as stress,
pollution, and smoking have resulted in decreased fertility in
females, thus propelling the demand for PGD and IVF. Various
innovations for the prevention of cancer and developments within the
genetics field have emerged as key growth opportunities in the market
for PGD.
On the other hand, the limited insurance coverage for PGD and IVF has
deterred patients from availing these techniques, hence inhibiting
the development of the market. In addition, the social and economic
factors associated with the usage of IVF will negatively impact the
market.
On the basis of test type, the report segments the market into PGD
for chromosomal aberrations, PGD for aneuploidy screening, PGD for
single gene disorder, PGD for gender selection, PGD for X-linked
diseases, and PGD for HLA typing. Amongst these, PGD for aneuploidy
screening led the market in 2013 owing to the fact that aneuploidy
can result in severe abnormalities.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=427
In aneuploidy screening during prenatal testing, if the detection of
chromosomal abnormality takes place in the fetus, the pregnancy gets
terminated. However, this disadvantage is fixed by opting for
preimplantation genetic diagnosis because genetic screening for
aneuploidy takes place before the implantation of the embryo takes
place and the pregnancy is conceived.
By geography, the global PGD market is segmented into Europe, Asia
Pacific, North America, and Rest of the World (RoW). Amongst these,
Europe led the market for PGD in 2013 owing to the soaring count of
IVF cycles and the rising awareness amongst patients within this
region. On the other hand, North America is predicted to expand at
the highest growth rate in the forecast horizon. In Latin America,
Africa, and Asia Pacific, increasing restrictions on fetus gender
detection and selection of X-linked diseases may hamper the
development of the market.
According to the report, the major players operating in the market
are Genesis Genetics, Illumina, Inc., Natera, Inc., Quest
Diagnostics, Inc., and Reproductive Genetics Institute, among
others.
Request for the TOC of the Report @
https://www.transparencymarketresearch.com/report-toc/427
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment